New vaccine against meningococcal infection for ages 2 to 59
Part of Brain & nervous system, Infections clinical trials.
This study tests a new vaccine that may protect against several types of meningococcal bacteria, which can cause serious infections like meningitis. It is given as a single shot to healthy people aged 2 to 59 years.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can be between 2 and 59 years old.
- You must be in generally good health.
- You must not have had a severe allergic reaction to any vaccine before.
- You must not have had meningitis (a serious brain infection) before.
- You must not be taking drugs that weaken the immune system, like high-dose steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a vaccine that protects against four types of meningococcal bacteria (groups A, C, W, and Y) in healthy babies aged 3 to 5 months. The vaccine is given to help prevent meningitis and other serious infections.
This study tests a vaccine that protects against four common types of meningitis (groups A, C, Y, and W135) in toddlers aged 12–23 months. It helps researchers see if the vaccine is safe and works well for young children.
This study tests whether a new vaccine safely protects infants aged 6 to 11 months against four types of meningococcal bacteria that can cause serious infections like meningitis and blood infections. It is designed for healthy babies who have not yet received any meningococcal vaccine.
This study tests an experimental vaccine to protect babies and toddlers from meningitis (a serious infection of the brain and spinal cord). It checks how well the vaccine works and how safe it is in young children.
This trial tests a new meningitis vaccine (GNG-DE) to see how well it works compared to a vaccine already on the market. It might help protect you or your child from meningococcal disease.
This trial tests a new meningococcal conjugate vaccine (EG-MCV4) in healthy adults to see how well the body's immune system responds and if it's safe. If you qualify, you'd help researchers learn if this vaccine can prevent meningococcal disease.
Hear when a new Meningococcal Meningitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.